Navigation Links
Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
Date:1/29/2008

fessionalism in the sports nutrition sector.

The final set of results from Millennium's sponsored Division 1 Football trial at Rutgers University have shown that Surgex(TM) had a significant effect on recovery markers including testosterone:cortisol ratios compared to a market leading sports beverage on the market. "Along with our previous statistically significant improvements in body composition and strength parameters, the recovery marker data continues to validate Surgex(TM) as an important nutritional adjunct for the athlete" states Mr. Germano. "As we have seen in the medical market, Surgex is now able to offer the athlete a product that will assist in recovery in efforts to improve performance. In addition, our participation in the BSCG program continues to set us apart from the competition."

The continued usage and acceptability of Surgex(TM) by Professional, Olympic, and Collegiate athletes is providing the valuable market information which will allow Millennium to develop the best strategy to commercialize Surgex(TM), expected in Q3 of 2008.

About Surgex(TM):

Surgex(TM) (http://www.surgexsports.com) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States The proprietary Surgex(TM) formula intends to meet the growing demand of elite level Professional, Olympic and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab Surgex(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflamma
'/>"/>

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
4. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
5. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Health, Inc. (Nasdaq: GHDX ) today announced plans ... improving the quality of diagnosis, communication and support for millions ... genetic conditions.   The subsidiary is expected to be established by ... 2013.  The new venture will be led by Randy Scott, ...
... 2012 TeDan Surgical Innovations , industry leader ... Phantom Series MIS Anterior Hip Retractor System . ... adjustable surgical arms with attachable retractors, enabling surgeons to ... a surgical assistant. Dr. Lawrence Menendez ...
Cached Medicine Technology:Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4New Minimally Invasive Hip Retractor Revolutionizes Anterior Hip Replacement Procedures 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... July 12, 2014 For those who are ... can readily absorb the nutrients in food. The enzymes literally ... are small enough to be absorbed by human bodies. According ... lack of enzymes in regular food is the cause of ... that was started by Michelle DelPresto, a mother of 3 ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
(Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... ... customers with an advanced BlackBerry® smartphone paging solution. Onset METAMessage® enables Indiana Paging Network ... RIMM) via their current pager number and eliminate the need to carry two devices. ... (PRWEB) April ...
... the number of preventable patient injuries in California hospitals ... drop in malpractice claims against physicians, according to a ... Researchers studied both medical malpractice claims and adverse events ... that changes in the frequency of adverse events were ...
... Experimental treatment offers hope against cancer that returns after castration ... that a new hormone treatment could be a weapon for ... that,s resistant to surgical removal of the testicles. , ... new drug treatments have been completed, however. At this point, ...
... ... comprehensive and successful anti-obesity program, First Lady Michelle Obama’s “Let’s Move” campaign must ... , ... (Vocus) April 14, 2010 -- To be a truly comprehensive and successful ...
... , ... the impact of statins on the progression of multiple sclerosis found a lower incidence of ... disease as compared to a placebo. , ... (Vocus) April 14, 2010 -- A UCSF-led study examining the impact of statins ...
... unsavory-sounding name "corn smut" wields different weapons from its ... it infects. The discovery by Stanford researchers marks the ... pathogen. The finding upends conventional notions of how ... approaches to fighting disease not only in plants but ...
Cached Medicine News:Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 2Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 3Health News:Better patient safety linked to fewer medical malpractice claims in California 2Health News:Hormone Therapy May Fight Resistant Prostate Cancer 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 4Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 2Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 3Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 4Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 2Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 3Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 4
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Testing for Strabismus (ocular misalignment) just became easier. By simply placing the StrabismoScope over the patient's eye, the examiner is able to observe the occluded eye directly, but the patien...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Medicine Products: